My guess is many investors would value having a pharmaceutical stock as part diversified portfolio.
AstraZeneca (LSE: AZN) and GSK (LSE: GSK) are two obvious contenders. But which is best for a long-term holding period?
The businesses have different characteristics. Therefore, choosing one over the other may depend on an investorâs strategy.
Decent dividend income
Those focused on dividend income might opt for GSK. With the share price near 1,506p, the forward-looking yield is around 4% for 2024.
But weâve yet to see how the business settles down after the recent separation from its consumer healthcare business (now Haleon). GSK is now more driven by research & development (R&D) than it was. And the dividend record shows the changes in the enterprise with recent declines in the shareholder payment.
Itâs only in 2024 that City analysts expect the dividend to rise again by a modest single-digit percentage. And for a dividend-led investment, Iâd prefer to see a record of steady dividend growth. But GSK has still to prove its dividend credentials going forward.
Meanwhile, AstraZenecaâs dividend record is steady with modest rises most years. However, with the share price near 11,063p, the yield is quite low. Looking ahead, investors can expect around 2.36% for 2024.
Strong growth in earnings
But AstraZenecaâs R&D pipeline has been delivering the goods for some time. And the company keeps developing new medicines that have been selling well. Forecasts for earnings growth are impressive â around 90% this year and about 16% in 2024.
Investors focused on growth might opt for shares in AstraZeneca.
Meanwhile, City analysts expect an improvement of around 30% in earnings at GSK this year and around 4% in 2024. Itâs still progress, but itâs way behind the AstraZeneca performance.
And the growth situation helps to explain the valuation differences. The forward-looking earnings multiple for AstraZeneca is around 16 for 2024. But GSKâs is just below 10.
By traditional valuation measures, GSK looks cheaper than AstraZeneca. However, valuation often reflects growth prospects, and I think it does with these two companies.
Nevertheless, GSK may find its growth mojo in the coming years. Back in Jul, chief executive Emma Walmsley reported âanother excellent quarter of performance, with strong sales and earnings growth, notably in HIV and Vaccines.â And there was âcontinued strengthening of the R&D pipeline and product portfolio.â
If the company can build momentum in its R&D pipeline, a value purchase of the stock today could end up being clever.
R&D is key for both companies
Several years ago, AstraZeneca looked similar to GSK now. But the company went on to deliver strong growth for its shareholders as can be seen in the chart:
However, positive outcomes are not certain for either company. And perhaps the biggest risk for investors in both cases is the ongoing performance of the R&D pipelines.
For example, a series of failures and a drying up of commercially successful product launches could sink either of the companiesâ share prices and dividend streams.
Nevertheless, I think both businesses look attractive and I would consider them for a diversified portfolio of long-term stock holdings. As to which is best, Iâm tempted by GSK. But Iâd be happy owning either stock.
The post Which is the best value stock now: AstraZeneca or GSK? appeared first on The Motley Fool UK.
Pound coins for sale — 51 pence?
This seems ridiculous, but we almost never see shares looking this cheap. Yet this recent ‘Best Buy Now’ has a price/book ratio of 0.51. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 51p they invest!
Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.
What’s more, it currently boasts a stellar dividend yield of around 8.5%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?
See the full investment case
setButtonColorDefaults(“#5FA85D”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43A24A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#FFFFFF”, ‘color’, ‘#FFFFFF’);
})()
More reading
Up 14%! Are GSK shares set to soar?
Was selling our GSK shares a big mistake?
Three red hot LSE shares Iâd consider buying before the next stock market rallyÂ
2 FTSE 100 dividend stocks! Which should I buy for a second income?
Down 14%! Should I buy the dip in the AstraZeneca share price?
Kevin Godbold has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca Plc, GSK, and Haleon Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
